肝细胞癌根治性治疗后CT或MRI未见明显复发但甲胎蛋白升高的患者的临床结局
该回顾性研究纳入121例肝细胞癌根治性手术切除或射频消融后监测期间甲胎蛋白升高(>20 ng/mL)但多期CT或MRI未见明显复发的患者,中位至影像学复发时间为20.0个月(95% CI 13.0-28.0个月),6个月和1年累积影像学复发率分别为24.4%和40.1%;甲胎蛋白升高晚于治疗后3个月及下次随访甲胎蛋白未恢复正常均为至影像学复发的独立预测因素。
要点
- 肝癌根治性治疗后AFP>20 ng/mL而CT/MRI未见复发者,中位20.0个月出现影像学复发。
- 此类患者6个月和1年累积影像学复发率分别为24.4%和40.1%。
- AFP升高晚于治疗后3个月者至影像学复发更短(HR 2.11)。
核心结论
- 肝癌根治性治疗后监测中,AFP升高但CT或MRI未见明显复发者可能频繁进展为影像学可见复发。
- 高危患者需广泛诊断检查或密切监测以更早发现HCC复发。
研究设计与样本
- 回顾性分析121例肝癌根治性手术切除或射频消融后监测期间AFP>20 ng/mL且多期CT或MRI未见明显复发的患者。
- 采用Kaplan-Meier法估计自首次AFP升高至影像学复发的时间(TimeAFP-Imaging recurrence)。
- 采用Cox回归分析评估与TimeAFP-Imaging recurrence相关的因素。
诊断标准与关键数值
- 甲胎蛋白升高定义为治疗后AFP>20 ng/mL。
- 中位至影像学复发时间为20.0个月(95% CI 13.0-28.0个月)。
- 估计6个月累积影像学复发率为24.4%,1年累积影像学复发率为40.1%。
- 使用首次AFP升高时可获得变量,AFP升高晚于治疗后3个月是至影像学复发更短的独立预测因素(HR 2.11,P=0.015)。
- 使用包含随访数据的变量,下次随访时AFP未恢复正常是至影像学复发更短的独立预测因素(HR 3.65,P<0.001)。
临床应用与阅片要点
- 肝癌根治性治疗后AFP>20 ng/mL而多期CT或MRI未见明显复发时,应警惕后续影像学复发可能。
- 作者认为,高危患者需广泛诊断检查或密切监测以更早发现HCC复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Multiphasic CT or MRI and serum alpha-fetoprotein (AFP) are widely used for posttreatment surveillance of hepatocellular carcinoma (HCC). This study aimed to investigate the clinical outcomes of patients with high posttreatment AFP but without evident recurrence on CT or MRI after curative-intent treatment of HCC.
METHODS: We retrospectively analyzed 121 patients presenting with high posttreatment AFP (> 20 ng/mL) without evident recurrence on multiphasic CT or MRI during surveillance after curative-intent surgical resection or radiofrequency ablation (RFA) for HCC. The time interval from the first event of high posttreatment AFP to imaging-evident recurrence (TimeAFP-Imaging recurrence) was estimated using the Kaplan-Meier method. Cox regression analyses were performed to assess the associated factors with TimeAFP-Imaging recurrence.
RESULTS: The median TimeAFP-Imaging recurrence was 20.0 months (95% CI 13.0-28.0 months), and the estimated 6-month and 1-year cumulative incidences of imaging-evident recurrence were 24.4% and 40.1%, respectively. In multivariate Cox analyses, late onset of AFP elevation (> 3 months after treatment) was an independent predictor of shorter TimeAFP-Imaging recurrence (HR 2.11, P = 0.015) if using variables available at the first event of AFP elevation, while non-normalization of AFP at the next follow-up was an independent predictor of shorter TimeAFP-Imaging recurrence (HR 3.65, P < 0.001) if using variables including the follow-up data.
CONCLUSION: In the surveillance setting after curative-intent treatment of HCC, patients presenting with high posttreatment AFP without evident recurrence on CT or MRI may frequently progress to imaging-evident recurrence. In high-risk patients, an extensive diagnostic workup or close monitoring is needed to detect HCC recurrence earlier.
引用
- Lee J, Joo I, Lee DH, et al. Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma. Abdom Radiol (NY). 2020. PMID: 32812065. doi:10.1007/s00261-020-02707-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。